Diagnostics & Research · San Antonio, Texas, United States
$0.77
-2.47% (-$0.02)2026-07-10
Revenue$1.4M
Net Income-$3.6M
EPS$-0.81
Market Cap$3.4M
Price Performance
Historical data including institutional events
Company Profile
M
Maria Zannes
CEO & Executive Director
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a personâs sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
